Johnson & Johnson

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals. Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative

17 November 2025

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson Stock Primed for Rally? Premarket Insights for Nov 3, 2025

Earnings & Guidance Lift Hopes Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex ($3.67B) and its autoimmune blockbusters driving growth ts2.tech reuters.com. Adjusted EPS of $2.80 beat forecasts, and management raised full-year 2025 product revenue guidance to $93.5–93.9B reuters.com. Such beats and raises were well-received: on Oct. 14 JNJ stock spiked ~2%, closing near $191 ts2.tech. Analysts point out that JNJ now expects 2026 sales growth above 5%, reflecting confidence in its new drug launches and MedTech momentum ts2.tech investing.com. Even as

2 November 2025

Financial News · Investing · Johnson & Johnson · Premarket Analysis · Stock Market

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company, Kenvue (KVUE). Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means J&J will remain focused on pharmaceuticals and higher-growth medical devices, while DePuy Synthes (named after J&J’s long-time orthopedics brand) inherits the hip/knee/shoulder implant and surgical tools business reuters.com jnj.com. Spin-offs are commonly used to allow each entity to pursue tailored

14 October 2025

Business News · Corporate Strategy · Healthcare · Industry Trends · Medical Devices · NYSE:JNJ · NYSE:KVUE